TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study

Mitchell Emmers, Marij J. P. Welters, Michelle V. Dietz, Saskia J. Santegoets, Sanne Boekesteijn, Anouk Stolk, Nikki M. Loof, Daphne W. Dumoulin, Annemarie L. Geel, Lauri C. Steinbusch, A. Rob P. M. Valentijn, Danielle Cohen, Noel F. C. C. de Miranda, Egbert F. Smit, Hans Gelderblom, Thorbald van Hall, Joachim G. Aerts and Sjoerd H. van der Burg ()
Additional contact information
Mitchell Emmers: Erasmus University Medical Center
Marij J. P. Welters: Leiden University Medical Center
Michelle V. Dietz: Erasmus University Medical Center
Saskia J. Santegoets: Leiden University Medical Center
Sanne Boekesteijn: Leiden University Medical Center
Anouk Stolk: Leiden University Medical Center
Nikki M. Loof: Leiden University Medical Center
Daphne W. Dumoulin: Erasmus University Medical Center
Annemarie L. Geel: Erasmus University Medical Center
Lauri C. Steinbusch: Leiden University Medical Center
A. Rob P. M. Valentijn: Leiden University Medical Center
Danielle Cohen: Leiden University Medical Center
Noel F. C. C. de Miranda: Leiden University Medical Center
Egbert F. Smit: Leiden University Medical Center
Hans Gelderblom: Leiden University Medical Center
Thorbald van Hall: Leiden University Medical Center
Joachim G. Aerts: Erasmus University Medical Center
Sjoerd H. van der Burg: Leiden University Medical Center

Nature Communications, 2025, vol. 16, issue 1, 1-14

Abstract: Abstract Functional loss of the intracellular peptide Transporter associated with Antigen Processing (TAP) fosters resistance to T-cell based immunotherapy. We discovered the presentation of an alternative set of shared tumor antigens on such escaped cancers and developed a LRPAP1 synthetic long peptide vaccine (TEIPP24) to stimulate T-cell immunity. In this first-in-human multicenter dose-escalation study with extension cohort, HLA-A*0201-positive patients with non-small cell lung cancer progressive after checkpoint blockade were treated with TEIPP24 (NCT05898763). Dose escalation followed an adapted 3 + 3 scheme where in each cohort six patients received the TEIPP24 peptide emulsified in Montanide ISA-51 at either 20, 40, 100 µg of peptide, subcutaneously injected three times every three weeks in alternating limbs. The extension cohort of six patients received the highest safe dose of TEIPP24 combined with the PD-1 checkpoint blocker pembrolizumab. The primary objectives of the study were safety, tolerability and immunogenicity of the TEIPP24 vaccine. Secondary objectives included the evaluation of specificity and immune modulatory effects of the vaccine, antigen and immune status of the patients, progression free (PFS) and overall survival (OS) and radiological tumor response rate and duration. A total of 26 patients were enrolled across 2 institutions. Treatment was well tolerated, and vaccine-induced LRPAP1-specific CD8+ T cells were detected in 20 of 24 evaluable patients (83%). In 13 of 21 tested cases (62%) vaccine-specific CD4+ T cells were also detected. The increase in activated polyfunctional CD8+ effector T cells was influenced by vaccine dose, number of vaccines administered, induction of a CD4+ T-cell response, and the pre-existing frequency of monocytic cells. Co-administration of pembrolizumab resulted in the ex-vivo detection of activated (HLA-DR+ , PD-1+ , ICOS+ ) LRPAP1-specific CD8+ T cells. The observation of one PR, 8 stable diseases and 2 mixed responses in 24 evaluable patients after vaccination, correlated with a stronger vaccine-induced CD8+ T-cell response to this single epitope from this new class of cancer antigens.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60281-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60281-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60281-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().